Ashvattha Therapeutics, Inc.

📍 Redwood City, United States🗓 Founded 2015👥 23 employees💰 Last funded 2024
Pharmaceutical Manufacturing🌐 avttx.com
Website LinkedIn
Ashvattha Therapeutics is developing a new class of drugs that identify and treat diseased cells with unprecedented precision. Our proprietary hydroxyl dendrimer (HD) platform, exclusively licensed from Johns Hopkins University, allows for the creation of hydroxyl dendrimer therapeutics (HDTs), which link known small molecule drugs to HDs for selective delivery with sustained effect in diseased tissues. We believe this approach to precision medicine has the potential to change the standard of care across neurology, ophthalmology, hyperinflammatory diseases and neuro-oncology.
10
Total investors
0
Early stage
8
Mid stage
2
Late stage
2015
Founded

Investors

10 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
9
India
1
Investor activity2018–2024 · investors recorded per year
2018120191202062023120241
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Ashvattha Therapeutics, Inc.?
Ashvattha Therapeutics, Inc. has 10 investors on record on gritt.io, 8 mid-stage and 2 late-stage investors.
When did Ashvattha Therapeutics, Inc. last raise funding?
The most recent investment in Ashvattha Therapeutics, Inc. recorded on gritt.io was in 2024.
When was Ashvattha Therapeutics, Inc. founded?
Ashvattha Therapeutics, Inc. was founded in 2015.
What industry is Ashvattha Therapeutics, Inc. in?
Ashvattha Therapeutics, Inc. operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Ashvattha Therapeutics, Inc. based?
Ashvattha Therapeutics, Inc. is headquartered in Redwood City, United States.